Current Oncology Reports

, 9:9

The use of HER2 modulation in the adjuvant setting



Amplification of theher-2/neu gene is associated with poor prognosis in patients with early-stage and metastatic breast cancer. Trastuzumab is a humanized monoclonal antibody directed against the HER2 protein, which is overexpressed in approximately 25% of patients with primary invasive breast cancer. Randomized phase III clinical trials showed that administration of trastuzumab in combination with chemotherapy or following chemotherapy significantly improves disease-free and overall survival rates in patients with early-stage HER2-positive breast cancer. The integration of trastuzumab in the adjuvant setting is changing the natural history of HER2-driven breast cancer from one of the worst subtypes to one that is highly curable with available therapy.

References and Recommended Reading

  1. 1.
    Jemal AR, Siegel E, Ward, et al.:Cancer statistics, 2006.CA Cancer J Clin 2006,56:106–130.PubMedCrossRefGoogle Scholar
  2. 2.
    Gschwind A, Fischer OM, Ullrich A:The discovery of receptor tyrosine kinases: targets for cancer therapy.Nat Rev Cancer 2004,4:361–370.PubMedCrossRefGoogle Scholar
  3. 3.
    Slamon DJ, Clark GM, Wong SG, et al.:Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 1987,235:177–182.PubMedCrossRefGoogle Scholar
  4. 4.
    Slamon DJ, Godolphin W, Jones LA, et al.:Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science 1989,244:707–712.PubMedCrossRefGoogle Scholar
  5. 5.
    Carter P, Presta L, Gorman CM, et al.:Humanization of an anti-p185HER2 antibody for human cancer therapy.Proc Natl Acad Sci U S A 1992,89:4285–4289.PubMedCrossRefGoogle Scholar
  6. 6.
    Slamon DJ, Leyland-Jones B, Shak S, et al.:Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med 2001,344:783–792.PubMedCrossRefGoogle Scholar
  7. 7.
    Marty M, Cognetti F, Maraninchi D, et al.:Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.J Clin Oncol 2005,23:4265–4274.PubMedCrossRefGoogle Scholar
  8. 8.
    Vogel CL., Cobleigh MA, Tripathy D, et al.:Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.J Clin Oncol 2002,20:719–726.PubMedCrossRefGoogle Scholar
  9. 9.
    Baselga J, Carbonell X, Castaneda-Soto NJ, et al.:Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.J Clin Oncol 2005,23:2162–2171.PubMedCrossRefGoogle Scholar
  10. 10.
    Romond EH, Perez EA, Bryant J, et al.:Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med 2005,353:1673–1684.PubMedCrossRefGoogle Scholar
  11. 11.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.:Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med 2005,353:1659–1672.PubMedCrossRefGoogle Scholar
  12. 12.
    Slamon D, Eiermann W, Robert N, et al.:Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005,94:S5a.Google Scholar
  13. 13.
    Joensuu H, Joensuu K.-L.P.-L., Bono P, et al.:Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer Trial.N Engl J Med 2006,354:809–820.PubMedCrossRefGoogle Scholar
  14. 14.
    Perez E:Special session: Monoclonal antibody therapy in breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005.Google Scholar
  15. 15.
    Smith IE, on behalf of the HERA study team: Scientificspecial session: Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): disease-free and overall survival after 2 year median follow-up. Presented at the American Society of Clinical Oncology Annual Meeting; 2006.Google Scholar
  16. 16.
    Pegram M, Hsu S, Lewis G, et al.:Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.Oncogene 1999,18:2241–2251.PubMedCrossRefGoogle Scholar
  17. 17.
    Pegram, MD, O’Callaghan C:Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.Clin Breast Cancer 2001,2(Suppl 1):S15-S19.PubMedCrossRefGoogle Scholar
  18. 18.
    Pegram MD, Lopez A, Konecny G, Slamon DJ:Trastuzumab and chemotherapeutics: drug interactions and synergies.Semin Oncol 2000,27:21–25; discussion 92–100.PubMedGoogle Scholar
  19. 19.
    Hortobagyi GN:Trastuzumab in the treatment of breast cancer.N Engl J Med 2005,353:1734–1736.PubMedCrossRefGoogle Scholar
  20. 20.
    Bendell JC, Domchek SM, Burstein HJ, et al.:Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.Cancer 2003,97:2972–2977.PubMedCrossRefGoogle Scholar
  21. 21.
    Hurley, J, Doliny P, Reis I, et al.:Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.J Clin Oncol 2006,24:1831–1838.PubMedCrossRefGoogle Scholar
  22. 22.
    Buzdar AU, Ibrahim NK, Francis D, et al.:Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.J Clin Oncol 2005,23:3676–3685.PubMedCrossRefGoogle Scholar
  23. 23.
    Seidman A, Hudis C, Pierri MK, et al.:Cardiac dysfunction in the trastuzumab clinical trials experience.J Clin Oncol 2002,20:1215–1221.PubMedCrossRefGoogle Scholar
  24. 24.
    Perez EA, Rodeheffer R:Clinical cardiac tolerability of trastuzumab.J Clin Oncol 2004,22:322–329.PubMedCrossRefGoogle Scholar
  25. 25.
    Tan-Chiu E, Yothers G, Romond E, et al.:Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.J Clin Oncol 2005,23:7811–7819.PubMedCrossRefGoogle Scholar
  26. 26.
    Crone SA, Zhao YY, Fan L, et al.:ErbB2 is essential in the prevention of dilated cardiomyopathy.Nat Med 2002,8:459–465.PubMedCrossRefGoogle Scholar
  27. 28.
    Chien KR:Herceptin and the heart—a molecular modifier of cardiac failure.N Engl J Med 2006,354:789–790.PubMedCrossRefGoogle Scholar
  28. 28.
    Guarneri V, Lenihan D, Valero V, et al.:Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.J Clin Oncol 200624:4107–4115.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2007

Authors and Affiliations

  1. 1.Departments of Breast Medical Oncology and Molecular & Cellular OncologyUniversity of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations